Limited sampling strategy for the estimation of mycophenolic acid area under the concentration-time curve treated in Japanese living-related renal transplant recipients with concomitant extended-release tacrolimus

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 6, 2013, Pages 1036-1039

  Yamaguchi, Kazunori ^a   Fukuoka, Noriyasu ^a   Kimura, Sumio ^a   Watanabe, Masahiro ^a   Tani, Kumiko ^a   Tanaka, Hiroaki ^a   Sofue, Tadashi ^b   Kosaka, Shinji ^a   Inui, Masashi ^c   Kakehi, Yoshiyuki ^b   Houchi, Hitoshi ^a  

^a KAGAWA UNIVERSITY HOSPITAL   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Area under the concentration time curve; Limited sampling strategy; Mycophenolate mofetil; Mycophenolic acid; Renal transplant recipient

Indexed keywords

ALBUMIN; CREATININE; GRACEPTOR CAPSULES; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGED; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG RELEASE; EXTENTED DRUG RELEASE; FEMALE; GRAFT RECIPIENT; HUMAN; JAPANESE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE;

ADULT; AGED; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD SPECIMEN COLLECTION; DELAYED-ACTION PREPARATIONS; DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS; YOUNG ADULT;

EID: 84878841021     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-01095     Document Type: Article

References (18)

1. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 47, 85-118 (2000).
2. Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am. J. Transplant., 9, 1607-1619 (2009).
3. Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, Hurault de Ligny B, Rostaing L, Thervet E, Szelag JC, Rérolle JP, Rousseau A, Touchard G, Marquet P. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am. J. Transplant., 7, 2496-2503 (2007).
4. van Gelder T, Tedesco Silva H, de Fijter JW, Budde K, Kuypers D, Arns W, Soulillou JP, Kanellis J, Zelvys A, Ekberg H, Holzer H, Rostaing L, Mamelok RD. Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation, 89, 595-599 (2010).
5. van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther. Drug Monit., 28, 145-154 (2006).
6. Hale MD, Nicholls AJ, Bullingham RE, Hené R, Hoitsma A, Squifflet JP, Weimar W, Vanrenterghem Y, Van de Woude FJ, Verpooten GA. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin. Pharmacol. Ther., 64, 672-683 (1998).
7. Barraclough KA, Isbel NM, Johnson DW, Hawley CM, Lee KJ, McWhinney BC, Ungerer JP, Campbell SB, Leary DR, Staatz CE. A limited sampling strategy for the simultaneous estimation of tacrolimus, mycophenolic acid and unbound prednisolone exposure in adult kidney transplant recipients. Nephrology (Carlton), 17, 294-299 (2012).
8. Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J. Clin. Pharmacol., 43, 866-880 (2003).
9. Le Guellec C, Büchler M, Giraudeau B, Le Meur Y, Gakoué JE, Lebranchu Y, Marquet P, Paintaud G. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur. J. Clin. Pharmacol., 57, 805-811 (2002).
10. Miura M, Satoh S, Niioka T, Kagaya H, Saito M, Hayakari M, Habuchi T, Suzuki T. Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients. Ther. Drug Monit., 30, 52-59 (2008).
11. Pawinski T, Hale M, Korecka M, Fitzsimmons WE, Shaw LM. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin. Chem., 48, 1497-1504 (2002).
12. Teshima D, Maiguma T, Kaji H, Otsubo K, Kitagawa N, Okabe Y, Sugitani A, Tanaka M, Oishi R. Estimation of the area under the curve for mycophenolic acid in adult renal transplant patients with concomitant tacrolimus using a limited sampling strategy. J. Clin. Pharm. Ther., 33, 159-163 (2008).
13. Schütz E, Armstrong VW, Shipkova M, Weber L, Niedmann PD, Lammersdorf T, Wiesel M, Mandelbaum A, Zimmerhackl LB, Mehls O, Tönshoff B, Oellerich M, German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. Transplant. Proc., 30, 1182-1184 (1998).
14. Yeung S, Tong KL, Tsang WK, Tang HL, Fung KS, Chan HW, Chan AY, Chan L. Determination of mycophenolate area under the curve by limited sampling strategy. Transplant. Proc., 33, 1052-1053 (2001).
15. Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepers R, Squifflet JP, Wallemacq P. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin. Chem., 47, 1241-1248 (2001).
16. Johnson AG, Rigby RJ, Taylor PJ, Jones CE, Allen J, Franzen K, Falk MC, Nicol D. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin. Pharmacol. Ther., 66, 492-500 (1999).
17. Naesens M, de Loor H, Vanrenterghem Y, Kuypers DR. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation, 84, 362-373 (2007).
18. Oellerich M, Shipkova M, Schütz E, Wieland E, Weber L, Tönshoff B, Armstrong VW. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. Ther. Drug Monit., 22, 20-26 (2000).